Table 2.
Name of peptide | Sequence of peptide | Binding scorea | Binding scoreb | Refolding | Reference |
HLA-B27/EBNA (258–266) (EBV) | RRIYDLIEL | 28 | 2000 | ++ | [24] |
HLA-A2/BMLF1 lytic antigen peptide 280–288 (EBV) | GLCTLVAML | 29 | 6000 | ++ | [21] |
HLA-B27/Influenza NP 383–391 | SRYWAIRTR | 26 | 1500 | + | [32] |
HLA-B27/Chlamydia peptide 8 | NRFSVAYML | 26 | 10,000 | ++ | [10] |
HLA-B27/Chlamydia peptide 68 | NRAKQVIKL | 26 | 2000 | (+) | [10] |
HLA-B27/Chlamydia peptide 80 | IRMFKILPL | 26 | 2000 | + | [10] |
HLA-B27/Chlamydia peptide 131 | KRLAETLAL | 26 | 6000 | (+) | [10] |
HLA-B27/Chlamydia peptide 133 | IRSSVQNKL | 27 | 2000 | (+) | [10] |
HLA-B27/Chlamydia peptide 138 | ARKLLLDNL | 26 | 2000 | ++ | [10] |
HLA-B27/Chlamydia peptide 144 | MRDHTITLL | 25 | 2000 | - | [10] |
HLA-B27/Chlamydia peptide 145 | DRLALLANL | 27 | 200 | + | [10] |
HLA-B27/Chlamydia peptide 146 | YRLLLTRVL | 25 | 600 | (+) | [10] |
HLA-B27/Chlamydia peptide 194 | EREQTLNQL | 25 | 200 | - | [10] |
HLA-B27/Chlamydia peptide 195 | NRELIQQEL | 25 | 2000 | (+) | [10] |
HLA-B27/Chlamydia peptide 196 | ERFLAQEQL | 27 | 1000 | (+) | [10] |
Refolding rates are designated as follows: ++, more than 75% soluble HLA-B27 monomer in gel-filtration analysis after refolding and biotinylation; +, more than 50% refolding; (+), more than 10% refolding; -, less than 10% refolding.
aSYFPEITHI, HG Rammensee, University of Tübingen [23].
bHLA-peptide binding motifs (the BioInformatics and Molecular Analysis Section; http://bimas.dcrt.nih.gov/molbio/hla_bind/). EBV, Epstein–Barr virus.